Rapid infectious disease test Xpert®

flufor Ebola virus diseasefor glycoproteins

Since the first discovery of Ebola virus in 1976, Ebola virus disease (EVD) has occurred sporadically throughout West Africa. EVD is a severe and highly contagious illness. The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks.2 However, the survival rate can improve dramatically with implementation of early supportive care.2 The Ebola outbreak has spread beyond Africa and reached Europe and the United States. The global outbreak of EVD heightens the need for a fast and accurate diagnostics Unprecedented sensitivity for detecting Ebola virus Dual target design, also found in the Cepheid’s Anthrax test*, ensures high accuracy Sample Reagent that reduces biohazard risk to manageable level^ On-demand results that empowers physicians to manage crisis Self-contained cartridge system that minimizes potential contamination The Impact Xpert® Ebola will accelerate your laboratory's workflow with on-demand, random-access flexibility. In combination with other available tests (including Xpert® Xpress Flu/RSV, Xpert® GBS, Xpert® MRSA NxG, Xpert® C. difficile, Xpert® CT/NG, Xpert® Xpress SARS-CoV-2, and Xpert® MTB/RIF Ultra), Cepheid's GeneXpert® System delivers proven productivity increases in overall laboratory service. Be Prepared Sensitive: can detect as few as 0.13 PFU/mL of Ebola Zaire Virus Simple sample processing makes the test ideal for emergency use Accepts whole blood (EDTA or finger-stick) or buccal swab specimens